PO:13:336 Improvement of fatigue, musculoskeletal pain, morning stiffness and health-related quality of life in patients with SLE treated with dapirolizumab pegol: 48-week results from a phase 3 trial

Mean values of kidney function and serological lupus markers at baseline and at week 52 are summarised in table 1. Importantly, the mean prednisolone use was reduced to 5.8 mg.Two patients were able to discontinue corticosteroid therapy.Nine patients developed hypertension and were subsequently initiated on antihypertensive therapy.During the 52-week treatment, voclosporin was discontinued in one patient after 9 months due to hospitalisation for sepsis, which was deemed unrelated to the medication.Conclusions Voclosporin was well tolerated, and the majority of the patients demonstrated satisfactory medication compliance.The therapy showed a significant reduction in proteinuria and lupus serology markers, allowing a decrease in steroid use.However, the patient developed hypertension after voclosporin initiation, requiring closer blood pressure monitoring.Our real-world use of voclosporin outside a clinical trial setting shows positive renal outcomes similar to those demonstrated in large-scale trials and enables dose reduction in steroids.